Myriad Genetics' GAAP loss for 3 months of 2022 was $20.5 million, down 48.1% from $39.5 million in the previous year. Revenue decreased 4.7% to $164.9 million from $173.1 million a year earlier.

Myriad Genetics' GAAP loss for 2021 was $27.2 million, down 8.3 times from $223.7 million in the previous year. Revenue increased 24% to $690.6 million from $557.1 million a year earlier.

The loss of Myriad Genetics under GAAP for the nine months of 2021 was $19.6 million, down 9.3 times from $185.9 million in the previous year. Revenues increased 31.7% to $529.8 million from $402.4 million a year earlier.

Myriad Genetics has completed the sale to Labcorp of a portion of its autoimmune business assets and related intellectual property, including the Vectra rheumatoid arthritis test. The transaction amounted to $150 million.